Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.

× No keyword cloud information.

17 in total

1. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Authors: Justin F Gainor; Daniel S W Tan; Tomasso De Pas; Benjamin J Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y Yeap; Jeffrey A Engelman; Alice T Shaw
Journal: Clin Cancer Res Date: 2015-02-27 Impact factor: 12.531

2. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

Authors: David R Gandara; Tianhong Li; Primo N Lara; Karen Kelly; Jonathan W Riess; Mary W Redman; Philip C Mack
Journal: Clin Lung Cancer Date: 2013-10-12 Impact factor: 4.785

Review 3. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

Authors: Raymond Pagliarini; Wenlin Shao; William R Sellers
Journal: EMBO Rep Date: 2015-02-13 Impact factor: 8.807

Review 4. A Convergence-Based Framework for Cancer Drug Resistance.

Authors: David J Konieczkowski; Cory M Johannessen; Levi A Garraway
Journal: Cancer Cell Date: 2018-05-14 Impact factor: 31.743

5. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

Authors: Cecile Bosc; Gilbert R Ferretti; Jacques Cadranel; Clarisse Audigier-Valette; Benjamin Besse; Fabrice Barlesi; Chantal Decroisette; Sylvie Lantuejoul; François Arbib; Denis Moro-Sibilot
Journal: Target Oncol Date: 2014-08-15 Impact factor: 4.493

Review 6. Resisting Resistance: Targeted Therapies in Lung Cancer.

Authors: Jessica J Lin; Alice T Shaw
Journal: Trends Cancer Date: 2016-07

Review 7. Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors: D Ross Camidge; William Pao; Lecia V Sequist
Journal: Nat Rev Clin Oncol Date: 2014-07-01 Impact factor: 66.675

Review 8. The pharmacogenomics of drug resistance to protein kinase inhibitors.

Authors: Nancy K Gillis; Howard L McLeod
Journal: Drug Resist Updat Date: 2016-07-05 Impact factor: 18.500

9. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.

Authors: Gregory N Gan; Andrew J Weickhardt; Benjamin Scheier; Robert C Doebele; Laurie E Gaspar; Brian D Kavanagh; D Ross Camidge
Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038

Review 10. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

Authors: Howard West; Geoffrey R Oxnard; Robert C Doebele
Journal: Am Soc Clin Oncol Educ Book Date: 2013